InvestLog
NAUT Nautilus Biotechnology, Inc. logo

NAUT Nautilus Biotechnology, Inc.

Healthcare
$2.54+0.00%ClosedMarket Cap: $322.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.23

P/S

0.00

EV/EBITDA

-6.00

DCF Value

$-0.15

FCF Yield

-15.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-35.0%

ROA

-32.1%

ROIC

-37.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-14.7M$—
Q4 null$0.00$-13.8M$—
FY null$0.00$-59.0M$—
Q3 null$0.00$-13.6M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.50

Target (Median)

$2.50

Target Range

$2.50 - $2.50

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
GuggenheimBuy
2026-02-27

Trading Activity

Insider Trades

View All
Weld Gwen Eofficer: Chief People Officer
SellWed Mar 04
Suzuki Kentaroofficer: Chief Marketing Officer
SellWed Mar 04
Sankar Subramanianofficer: Senior VP, Product Development
SellWed Mar 04
Patel Sujal Mdirector, 10 percent owner, officer: CEO, President, and Secretary
BuyWed Mar 04
Patel Sujal Mdirector, 10 percent owner, officer: CEO, President, and Secretary
SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.75

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Peers

ARCT logoARCTASMB logoASMBENTA logoENTAFHTX logoFHTXHUMA logoHUMAIMRX logoIMRXPYXS logoPYXSSGMT logoSGMTTNYA logoTNYAZURA logoZURA